Astria Therapeutics, Inc. (NASDAQ:ATXS – Get Rating) – Equities researchers at Wedbush issued their Q1 2023 earnings estimates for shares of Astria Therapeutics in a research note issued to investors on Friday, May 13th. Wedbush analyst L. Chico anticipates that the biotechnology company will post earnings per share of ($0.72) for the quarter. Wedbush also issued estimates for Astria Therapeutics’ Q2 2023 earnings at ($0.79) EPS, Q3 2023 earnings at ($0.90) EPS and Q4 2023 earnings at ($0.81) EPS.
Astria Therapeutics (NASDAQ:ATXS – Get Rating) last released its earnings results on Thursday, May 12th. The biotechnology company reported ($1.18) earnings per share for the quarter, missing the consensus estimate of ($0.84) by ($0.34).
Other equities research analysts have also recently issued research reports about the company. Zacks Investment Research cut Astria Therapeutics from a “hold” rating to a “sell” rating in a research note on Friday. HC Wainwright reissued a “buy” rating and issued a $13.00 price target on shares of Astria Therapeutics in a research note on Friday, March 11th.
NASDAQ:ATXS opened at $4.10 on Monday. The stock has a market cap of $53.37 million, a PE ratio of -0.52 and a beta of 1.38. The stock’s 50-day moving average is $6.27 and its two-hundred day moving average is $6.06. Astria Therapeutics has a fifty-two week low of $3.83 and a fifty-two week high of $15.72.
Institutional investors have recently made changes to their positions in the business. GSA Capital Partners LLP bought a new stake in Astria Therapeutics during the third quarter worth approximately $221,000. Commodore Capital LP bought a new stake in Astria Therapeutics during the third quarter worth approximately $2,115,000. Oppenheimer & Co. Inc. bought a new stake in Astria Therapeutics during the third quarter worth approximately $108,000. Artal Group S.A. bought a new stake in Astria Therapeutics during the third quarter worth approximately $295,000. Finally, BlackRock Inc. bought a new stake in Astria Therapeutics during the third quarter worth approximately $363,000. 51.79% of the stock is owned by hedge funds and other institutional investors.
About Astria Therapeutics (Get Rating)
Astria Therapeutics, Inc, a biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics for rare and niche allergic, and immunological diseases in the United States. Its lead product candidate is STAR-0215, a monoclonal antibody inhibitor of plasma kallikrein, which is in preclinical development stage for the treatment of hereditary angioedema.
Receive News & Ratings for Astria Therapeutics Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Astria Therapeutics and related companies with MarketBeat.com’s FREE daily email newsletter.